New Device Promises Better Pain Readings in Surgery
Published Date: 6/1/2026
Rule
Summary
The FDA is officially putting the adjunctive pain measurement device for anesthesiology into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while making it easier for patients to get new, helpful technology. The new classification is effective June 1, 2026, and could speed up innovation without extra costs for makers.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
New Special Controls Require Validation
Manufacturers must meet specific special controls before marketing: provide clinical data validating algorithms (including accuracy vs a reference, data representativeness, evaluation of pain types, and separate validation datasets for machine-learning algorithms), perform software verification/validation and hazard analysis, non-clinical performance testing for signal quality, usability assessment, biocompatibility testing, and electrical/electromagnetic safety testing.
Adjunctive Pain Device Moved to Class II
The FDA classified the adjunctive pain measurement device for anesthesiology as Class II (special controls), effective June 1, 2026 (classification was applicable February 17, 2023). The device is subject to premarket notification (510(k)) and can serve as a predicate for future devices, which the FDA says reduces regulatory burdens and can speed innovation without imposing extra costs on makers.
Labeling Must Show Clinical Demographics
Labeling for these devices must include a summary of clinical validation data with participant demographics (age, sex, race or ethnicity, patient condition), anesthetic regimen (types and doses), summary of results, information on subpopulations that may have disparate performance, a description of what the device measures and outputs, compatible sensor types, warnings about sensor and patient-condition limitations, and recommendations emphasizing adjunctive use.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073 — Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14155 — Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments
The FDA is hosting a public hearing on September 14, 2026, to explore how psychedelic drugs might be used safely as future medicines. They want to hear from patients, doctors, and anyone interested before October 5, 2026, to help shape rules and support safe, supervised treatments. This could change how some mental health conditions are treated and might open new doors for therapy options.
2026-14158 — Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
The FDA just released new guidance to help drug makers design safe and smart clinical trials for psychedelic medicines, which could treat mental health and addiction issues. This update affects companies developing these drugs by giving clear rules to follow, speeding up research while keeping safety first. The guidance is effective now, and the FDA welcomes comments anytime, making it easier and clearer to bring these promising treatments to patients.
2026-14119 — Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Availability
The FDA just released new rules for companies making generic skin creams with steroids. These rules explain how to prove their products work just as well as the original ones by testing on real people’s skin. This update affects drug makers and helps speed up safe, affordable medicine options starting now.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
Previous / Next Documents
Previous: 2026-10904 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Orally Ingested Transient Device for Constipation
The FDA is officially putting the new swallowed device for constipation into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this cool innovation by cutting down red tape. The new rules took effect June 1, 2026, and could save companies time and money getting their devices approved.
Next: 2026-10907 — Medical Devices; Anesthesiology Devices; Classification of the Real-Time Ultrasound Anatomy Visualization and Labeling Device for Ultrasound Guided Regional Anesthesia
The FDA is officially classifying a new ultrasound device that helps doctors see and label anatomy in real-time during regional anesthesia as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change makes it easier and faster for patients to get access to this helpful technology without compromising safety. The new classification is effective June 1, 2026, and could save time and money for device makers and hospitals.